Okadaic acid inhibits the trichostatin A-mediated increase of human CYP46A1 neuronal expression in a ERK1/2-Sp3-dependent pathway

Journal of Lipid Research

Volumn 53, Issue 9, 2012, Pages 1910-1919

  Nunes, Maria João ^a   Moutinho, Miguel ^a   Milagre, Inês ^a,b   Gama, Maria João ^a   Rodrigues, Elsa ^a  

^a RESEARCH INSTITUTE FOR MEDICINES IMED ULISBOA   (Portugal)

^b BABRAHAM INSTITUTE   (United Kingdom)

Author keywords

Brain cholesterol metabolism; Cytochrome P450; Gene regulation; HDAC inhibitors; MAPK signaling pathway and protein phosphatase inhibition; SP transcription factors

Indexed keywords

CYTOCHROME P450; CYTOCHROME P450 46A1; MITOGEN ACTIVATED PROTEIN KINASE 1; MITOGEN ACTIVATED PROTEIN KINASE 3; OKADAIC ACID; PEPTIDE FRAGMENT; PHOSPHOPROTEIN PHOSPHATASE; TRANSCRIPTION FACTOR SP3; TRICHOSTATIN A; UNCLASSIFIED DRUG;

ARTICLE; CONTROLLED STUDY; CYP46A1 GENE; ENZYME ACTIVITY; ENZYME INHIBITION; ENZYME REGULATION; GENE; HUMAN; HUMAN CELL; INTRACELLULAR SIGNALING; NEUROBLASTOMA CELL; PRIORITY JOURNAL; PROMOTER REGION; PROTEIN BINDING; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN PHOSPHORYLATION; TREATMENT RESPONSE;

BRAIN; CELL LINE, TUMOR; CHOLESTEROL; ENZYME INDUCTION; GENE EXPRESSION REGULATION, ENZYMOLOGIC; HOMEOSTASIS; HUMANS; HYDROXAMIC ACIDS; MAP KINASE KINASE 1; MITOGEN-ACTIVATED PROTEIN KINASE 1; MITOGEN-ACTIVATED PROTEIN KINASE 3; NEURONS; OKADAIC ACID; ORGAN SPECIFICITY; PHOSPHOPROTEINS; PHOSPHORYLATION; PROMOTER REGIONS, GENETIC; SIGNAL TRANSDUCTION; SP3 TRANSCRIPTION FACTOR; STEROID HYDROXYLASES; TIME FACTORS; TRANSCRIPTION, GENETIC;

EID: 84864848297     PISSN: 00222275     EISSN: 15397262     Source Type: Journal    
DOI: 10.1194/jlr.M027680     Document Type: Article

References (52)

1. Lund, E. G., J. M. Guileyardo, and D. W. Russell. 1999. cDNA cloning of cholesterol 24-hydroxylase, a mediator of cholesterol homeostasis in the brain. Proc. Natl. Acad. Sci. USA. 96: 7238-7243. (Pubitemid 29299645)
2. Bjorkhem, I., D. Lutjohann, U. Diczfalusy, L. Stahle, G. Ahlborg, and J. Wahren. 1998. Cholesterol homeostasis in human brain: turnover of 24S-hydroxycholesterol and evidence for a cerebral origin of most of this oxysterol in the circulation. J. Lipid Res. 39: 1594-1600. (Pubitemid 28377923)
3. Lund, E. G., C. Xie, T. Kotti, S. D. Turley, J. M. Dietschy, and D. W. Russell. 2003. Knockout of the cholesterol 24-hydroxylase gene in mice reveals a brain-specific mechanism of cholesterol turnover. J. Biol. Chem. 278: 22980-22988. (Pubitemid 36830363)
4. Kotti, T. J., D. M. Ramirez, B. E. Pfeiffer, K. M. Huber, and D. W. Russell. 2006. Brain cholesterol turnover required for geranylgeraniol production and learning in mice. Proc. Natl. Acad. Sci. USA. 103: 3869-3874. (Pubitemid 43376647)
5. Kotti, T., D. D. Head, C. E. McKenna, and D. W. Russell. 2008. Biphasic requirement for geranylgeraniol in hippocampal long-term potentiation. Proc. Natl. Acad. Sci. USA. 105: 11394-11399.
6. Brown 3rd, J., C. Theisler, S. Silberman, D. Magnuson, N. Gottardi-Littell, J. M. Lee, D. Yager, J. Crowley, K. Sambamurti, M. M. Rahman, et al. 2004. Differential expression of cholesterol hydroxylases in Alzheimer's disease. J. Biol. Chem. 279: 34674-34681. (Pubitemid 39318097)
7. Famer, D., S. Meaney, M. Mousavi, A. Nordberg, I. Bjorkhem, and M. Crisby. 2007. Regulation of alpha- and beta-secretase activity by oxysterols: cerebrosterol stimulates processing of APP via the alpha-secretase pathway. Biochem. Biophys. Res. Commun. 359: 46-50. (Pubitemid 46844819)
8. Prasanthi, J. R., A. Huls, S. Thomasson, A. Thompson, E. Schommer, and O. Ghribi. 2009. Differential effects of 24-hydroxycholesterol and 27-hydroxycholesterol on beta-amyloid precursor protein levels and processing in human neuroblastoma SH-SY5Y cells. Mol. Neurodegener. 4: 1.
9. Hudry, E., D. Van Dam, W. Kulik, P. P. De Deyn, F. S. Stet, O. Ahouansou, A. Benraiss, A. Delacourte, P. Bougneres, P. Aubourg, et al. 2010. Adeno-associated virus gene therapy with cholesterol 24-hydroxylase reduces the amyloid pathology before or after the onset of amyloid plaques in mouse models of Alzheimer's disease. Mol. Ther. 18: 44-53.
10. Shafaati, M., R. O'Driscoll, I. Bjorkhem, and S. Meaney. 2009. Transcriptional regulation of cholesterol 24-hydroxylase by histone deacetylase inhibitors. Biochem. Biophys. Res. Commun. 378: 689-694.
11. Nunes, M. J., I. Milagre, M. Schnekenburger, M. J. Gama, M. Diederich, and E. Rodrigues. 2010. Sp proteins play a critical role in histone deacetylase inhibitor-mediated derepression of CYP46A1 gene transcription. J. Neurochem. 113: 418-431.
12. Milagre, I., M. J. Nunes, M. J. Gama, R. F. Silva, J. M. Pascussi, M. C. Lechner, and E. Rodrigues. 2008. Transcriptional regulation of the human CYP46A1 brain-specific expression by Sp transcription factors. J. Neurochem. 106: 835-849.
13. Milagre, I., M. J. Nunes, M. Castro-Caldas, M. Moutinho, M. J. Gama, and E. Rodrigues. 2012. Neuronal differentiation alters the ratio of Sp transcription factors recruited to the CYP46A1 promoter. J. Neurochem. 120: 220-229.
14. Milagre, I., M. J. Nunes, M. Moutinho, I. Rivera, A. Fuso, S. Scarpa, M. J. Gama, and E. Rodrigues. 2010. Chromatin-modifying agents increase transcription of CYP46A1, a key player in brain cholesterol elimination. J. Alzheimers Dis. 22: 1209-1221.
15. Waby, J. S., C. D. Bingle, and B. M. Corfe. 2008. Post-translational control of sp-family transcription factors. Curr. Genomics. 9: 301-311.
16. Espinos, E., A. Le Van Thai, C. Pomies, and M. J. Weber. 1999. Cooperation between phosphorylation and acetylation processes in transcriptional control. Mol. Cell. Biol. 19: 3474-3484. (Pubitemid 29193807)
17. Camarero, N., A. Nadal, M. J. Barrero, D. Haro, and P. F. Marrero. 2003. Histone deacetylase inhibitors stimulate mitochondrial HMG-CoA synthase gene expression via a promoter proximal Sp1 site. Nucleic Acids Res. 31: 1693-1703. (Pubitemid 36336571)
18. Zhang, Y., M. Liao, and M. L. Dufau. 2006. Phosphatidylinositol 3-kinase/protein kinase Czeta-induced phosphorylation of Sp1 and p107 repressor release have a critical role in histone deacetylase inhibitor-mediated derepression [corrected] of transcription of the luteinizing hormone receptor gene. Mol. Cell. Biol. 26: 6748-6761. (Pubitemid 44387626)
19. Chen, C. S., S. C. Weng, P. H. Tseng, and H. P. Lin. 2005. Histone acetylation-independent effect of histone deacetylase inhibitors on Akt through the reshuffling of protein phosphatase 1 complexes. J. Biol. Chem. 280: 38879-38887.
20. Zhang, Y., and M. L. Dufau. 2003. Dual mechanisms of regulation of transcription of luteinizing hormone receptor gene by nuclear orphan receptors and histone deacetylase complexes. J. Steroid Biochem. Mol. Biol. 85: 401-414. (Pubitemid 37011117)
21. Ammanamanchi, S., J. W. Freeman, and M. G. Brattain. 2003. Acetylated sp3 is a transcriptional activator. J. Biol. Chem. 278: 35775-35780. (Pubitemid 37102354)
22. Milagre, I., M. Olin, M. J. Nunes, M. Moutinho, A. Lovgren-Sandblom, M. J. Gama, I. Bjorkhem, and E. Rodrigues. 2012. Marked change in the balance between CYP27A1 and CYP46A1 mediated elimination of cholesterol during differentiation of human neuronal cells. Neurochem. Int. 60: 192-198.
23. Schreiber, E., P. Matthias, M. M. Muller, and W. Schaffner. 1989. Rapid detection of octamer binding proteins with 'mini-extracts', prepared from a small number of cells. Nucleic Acids Res. 17: 6419. (Pubitemid 19198635)
24. Mao, L., L. Yang, A. Arora, E. S. Choe, G. Zhang, Z. Liu, E. E. Fibuch, and J. Q. Wang. 2005. Role of protein phosphatase 2A in mGluR5-regulated MEK/ERK phosphorylation in neurons. J. Biol. Chem. 280: 12602-12610.
25. Hedou, G. F., K. Koshibu, M. Farinelli, E. Kilic, C. E. Gee, U. Kilic, K. Baumgartel, D. M. Hermann, and I. M. Mansuy. 2008. Protein phosphatase 1-dependent bidirectional synaptic plasticity controls ischemic recovery in the adult brain. J. Neurosci. 28: 154-162.
26. Kasler, H. G., J. Victoria, O. Duramad, and A. Winoto. 2000. ERK5 is a novel type of mitogen-activated protein kinase containing a transcriptional activation domain. Mol. Cell. Biol. 20: 8382-8389.
27. Gong, C. X., S. Shaikh, J. Z. Wang, T. Zaidi, I. Grundke-Iqbal, and K. Iqbal. 1995. Phosphatase activity toward abnormally phosphorylated tau: decrease in Alzheimer disease brain. J. Neurochem. 65: 732-738.
28. Qian, W., X. Yin, W. Hu, J. Shi, J. Gu, I. Grundke-Iqbal, K. Iqbal, C. X. Gong, and F. Liu. 2100. Activation of protein phosphatase 2B and hyperphosphorylation of Tau in Alzheimer's disease. J. Alzheimers Dis. 23: 617-627.
29. Zhu, X., C. A. Rottkamp, H. Boux, A. Takeda, G. Perry, and M. A. Smith. 2000. Activation of p38 kinase links tau phosphorylation, oxidative stress, and cell cycle-related events in Alzheimer disease. J. Neuropathol. Exp. Neurol. 59: 880-888.
30. Zhu, X., A. K. Raina, C. A. Rottkamp, G. Aliev, G. Perry, H. Boux, and M. A. Smith. 2001. Activation and redistribution of c-jun N-terminal kinase/stress activated protein kinase in degenerating neurons in Alzheimer's disease. J. Neurochem. 76: 435-441. (Pubitemid 32097021)
31. Pei, J. J., H. Braak, W. L. An, B. Winblad, R. F. Cowburn, K. Iqbal, and I. Grundke-Iqbal. 2002. Up-regulation of mitogen-activated protein kinases ERK1/2 and MEK1/2 is associated with the progression of neurofibrillary degeneration in Alzheimer's disease. Brain Res. Mol. Brain Res. 109: 45-55. (Pubitemid 36078372)
32. Lutjohann, D., A. Papassotiropoulos, I. Bjorkhem, S. Locatelli, M. Bagli, R. D. Oehring, U. Schlegel, F. Jessen, M. L. Rao, K. von Bergmann, et al. 2000. Plasma 24S-hydroxycholesterol (cerebrosterol) is increased in Alzheimer and vascular demented patients. J. Lipid Res. 41: 195-198. (Pubitemid 30117859)
33. Papassotiropoulos, A., D. Lutjohann, M. Bagli, S. Locatelli, F. Jessen, R. Buschfort, U. Ptok, I. Bjorkhem, K. von Bergmann, and R. Heun. 2002. 24S-hydroxycholesterol in cerebrospinal fluid is elevated in early stages of dementia. J. Psychiatr. Res. 36: 27-32. (Pubitemid 34037845)
34. Zuliani, G., M. P. Donnorso, C. Bosi, A. Passaro, E. Dalla Nora, A. Zurlo, F. Bonetti, A. F. Mozzi, and C. Cortese. 2011. Plasma 24S-hydroxycholesterol levels in elderly subjects with late onset Alzheimer's disease or vascular dementia: a case-control study. BMC Neurol. 11: 121.
35. Pages, G. 2007. Sp3-mediated VEGF regulation is dependent on phosphorylation by extra-cellular signals regulated kinases (Erk). J. Cell. Physiol. 213: 454-463. (Pubitemid 47509727)
36. Bergeron, F., E. T. Bagu, and J. J. Tremblay. 2011. Transcription of platelet-derived growth factor receptor alpha in Leydig cells involves specificity protein 1 and 3. J. Mol. Endocrinol. 46: 125-138.
37. Petrovic, I., N. Kovacevic-Grujicic, and M. Stevanovic. 2009. ZBP-89 and Sp3 down-regulate while NF-Y up-regulates SOX18 promoter activity in HeLa cells. Mol. Biol. Rep. 36: 993-1000.
38. Tsika, G., J. Ji, and R. Tsika. 2004. Sp3 proteins negatively regulate beta myosin heavy chain gene expression during skeletal muscle inactivity. Mol. Cell. Biol. 24: 10777-10791. (Pubitemid 39603134)
39. Seyed, M., and J. X. Dimario. 2008. Fibroblast growth factor receptor 1 gene expression is required for cardiomyocyte proliferation and is repressed by Sp3. J. Mol. Cell. Cardiol. 44: 510-519.
40. Bakovic, M., K. Waite, and D. E. Vance. 2003. Oncogenic Ha-Ras transformation modulates the transcription of the CTP:phosphocholine cytidylyltransferase alpha gene via p42/44MAPK and transcription factor Sp3. J. Biol. Chem. 278: 14753-14761. (Pubitemid 36799799)
41. Braun, H., R. Koop, A. Ertmer, S. Nacht, and G. Suske. 2001. Transcription factor Sp3 is regulated by acetylation. Nucleic Acids Res. 29: 4994-5000. (Pubitemid 34065414)
42. Sapetschnig, A., G. Rischitor, H. Braun, A. Doll, M. Schergaut, F. Melchior, and G. Suske. 2002. Transcription factor Sp3 is silenced through SUMO modification by PIAS1. EMBO J. 21: 5206-5215.
43. Ross, S., J. L. Best, L. I. Zon, and G. Gill. 2002. SUMO-1 modification represses Sp3 transcriptional activation and modulates its subnuclear localization. Mol. Cell. 10: 831-842. (Pubitemid 35335638)
44. Stielow, B., A. Sapetschnig, C. Wink, I. Kruger, and G. Suske. 2008. SUMO-modified Sp3 represses transcription by provoking local heterochromatic gene silencing. EMBO Rep. 9: 899-906.
45. Witt, O., K. Sand, and A. Pekrun. 2000. Butyrate-induced erythroid differentiation of human K562 leukemia cells involves inhibition of ERK and activation of p38 MAP kinase pathways. Blood. 95: 2391-2396. (Pubitemid 30167741)
46. Rivero, J. A., and S. E. Adunyah. 1998. Sodium butyrate stimulates PKC activation and induces differential expression of certain PKC isoforms during erythroid differentiation. Biochem. Biophys. Res. Commun. 248: 664-668. (Pubitemid 28404478)
47. Chu, S., C. A. Cockrell, and T. J. Ferro. 2003. Expression of alpha-ENaC2 is dependent on an upstream Sp1 binding motif and is modulated by protein phosphatase 1 in lung epithelial cells. Biochem. Biophys. Res. Commun. 303: 1159-1168. (Pubitemid 36390267)
48. Spengler, M. L., L. W. Guo, and M. G. Brattain. 2008. Phosphorylation mediates Sp1 coupled activities of proteolytic processing, desumoylation and degradation. Cell Cycle. 7: 623-630. (Pubitemid 351499001)
49. Whitmarsh, A. J. 2007. Regulation of gene transcription by mitogen-activated protein kinase signaling pathways. Biochim. Biophys. Acta. 1773: 1285-1298. (Pubitemid 47125975)
50. Liu, F., K. Iqbal, I. Grundke-Iqbal, S. Rossie, and C. X. Gong. 2005. Dephosphorylation of tau by protein phosphatase 5: impairment in Alzheimer's disease. J. Biol. Chem. 280: 1790-1796.
51. Liu, R., and J. Z. Wang. 2009. Protein phosphatase 2A in Alzheimer's disease. Pathophysiology. 16: 273-277.
52. Papassotiropoulos, A., D. Lutjohann, M. Bagli, S. Locatelli, F. Jessen, M. L. Rao, W. Maier, I. Bjorkhem, K. von Bergmann, and R. Heun. 2000. Plasma 24S-hydroxycholesterol: a peripheral indicator of neuronal degeneration and potential state marker for Alzheimer's disease. Neuroreport. 11: 1959-1962.